Kenneth Rosenfield

Barry T. Katzen,M.D. is the founder and chief medical executive emeritus of the Miami Cardiac & Vascular Institute, a system-wide center of excellence that is part of Baptist Health South Florida, the largest health system in South Florida. He is Chairman, Department of Interventional Radiology and professor of radiology and surgery, Herbert Wertheim College of Medicine, Florida International University; and holder of similar appointments at University of Miami, School of Medicine and University of South Florida, Morsani College of Medicine. Since its founding in 1987, the Miami Cardiac & Vascular Institute has served as a national model of success in multidisciplinary cooperation, and is one of the nation’s leading cardiac and vascular institutions.

He established the interventional radiology program, cardiac catheterization laboratory and noninvasive vascular laboratory at Alexandria Hospital in Virginia in 1976, where he pioneered the use of sophisticated video and audio technology to enhance the process of education for practitioners. He is credited with being the first to use “live patient demonstrations” in the United States, which became the benchmark for procedural education in endovascular therapy and many other procedural areas of medicine. Dr. Katzen is one of the pioneers of percutaneous transluminal angioplasty and peripheral thrombolysis for less invasive treatment of vascular disease and was part of the investigative team that lead to the approval of the first intravascular stent.He is one of the founders of interventional radiology as a specialty of medicine, performing the first renal angioplasty in the United States.

Dr. Rosenfield is an interventional cardiologist and vascular specialist performing complex cardiac and vascular interventions. He is Section Head for Vascular Medicine and Intervention in the Division of Cardiology at Massachusetts General Hospital. He earned a masters degree in Health Care Delivery Science from Dartmouth College. In addition to being a master clinician and interventionalist, Dr. Rosenfield has dedicated much of his career to educating fellows, residents, students, and colleagues. He is the recipient of the distinguished Laennec award for his outstanding teaching and mentorship. He is also a researcher and clinical trialist. He designed and served as national principle investigator for several landmark studies, including Aspire 2, Levant 2, Superb, ACT 1, and NIH BEST-CLI trial. He is a leader in the cardiovascular world, having been elected to the Board of Governors of American College of Cardiology, immediate past-President of the MA ACC Chapter, and immediate past-President of the Society for Cardiovascular Angiography and Interventions (SCAI). Dr. Rosenfield is a founding member of VIVA, a 501c3 organization, and sits on its board of directors. At Massachusetts General Hospital, he is the Medical director of the PERT Program, which he founded with his colleagues; he also founded the National PERT Consortium, a 501c3 organization dedicated to improving management, outcomes, and awareness of Pulmonary Embolism, and he served as its initial President; he remains a member of the PERT Consortium Executive Committee.

Dr. Rosenfield is an interventional cardiologist and vascular specialist performing complex cardiac and vascular interventions. He is Section Head for Vascular Medicine and Intervention in the Division of Cardiology at Massachusetts General Hospital. He earned a masters degree in Health Care Delivery Science from Dartmouth College. In addition to being a master clinician and interventionalist, Dr. Rosenfield has dedicated much of his career to educating fellows, residents, students, and colleagues. He is the recipient of the distinguished Laennec award for his outstanding teaching and mentorship. He is also a researcher and clinical trialist. He designed and served as national principle investigator for several landmark studies, including Aspire 2, Levant 2, Superb, ACT 1, and NIH BEST-CLI trial. He is a leader in the cardiovascular world, having been elected to the Board of Governors of American College of Cardiology, immediate past-President of the MA ACC Chapter, and immediate past-President of the Society for Cardiovascular Angiography and Interventions (SCAI). Dr. Rosenfield is a founding member of VIVA, a 501c3 organization, and sits on its board of directors. At Massachusetts General Hospital, he is the Medical director of the PERT Program, which he founded with his colleagues; he also founded the National PERT Consortium, a 501c3 organization dedicated to improving management, outcomes, and awareness of Pulmonary Embolism, and he served as its initial President; he remains a member of the PERT Consortium Executive Committee.

Dr. Robert A. Lookstein, MD, MHCDL, FSIR, FAHA, FSVM,
A 1995 graduate of the State University of New York Downstate Health Sciences University College of Medicine, Dr. Lookstein honed his skills through a rigorous residency in diagnostic radiology and a fellowship in vascular and interventional radiology at Mount Sinai Hospital. His association with Mount Sinai has been both enduring and impactful, culminating in his current roles as Professor of Radiology and Surgery at the Icahn School of Medicine and Executive Vice Chairman of the Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System .
Beyond his clinical and academic responsibilities, Dr. Lookstein is deeply invested in research that shapes the future of vascular care. He has been instrumental in several pivotal studies, including the VENITE VICI venous stent trial, the SAVAL study on drug-coated stents in lower leg arteries, the PRESERVE registry evaluating the safety and efficacy of Inferior Vena Cava filters, the InPACT AV trial evaluating the role of drug coated balloons for hemodialysis fistula maintenance, the STORM-PE trial evaluating the role of percutaneous thrombectomy for acute pulmonary embolism, and the NHLBI-funded BEST-CLI trial assessing endovascular revascularization for critical limb ischemia .
His leadership extends to the global stage, where he serves as the 2025–2026 President of the Society of Interventional Radiology (SIR). In this capacity, Dr. Lookstein advocates for a longitudinal clinical practice model in interventional radiology, emphasizing the importance of multidisciplinary teamwork and the integration of artificial intelligence to enhance patient outcomes .

Dr. Rosenfield is an interventional cardiologist and vascular specialist performing complex cardiac and vascular interventions. He is Section Head for Vascular Medicine and Intervention in the Division of Cardiology at Massachusetts General Hospital. He earned a masters degree in Health Care Delivery Science from Dartmouth College. In addition to being a master clinician and interventionalist, Dr. Rosenfield has dedicated much of his career to educating fellows, residents, students, and colleagues. He is the recipient of the distinguished Laennec award for his outstanding teaching and mentorship. He is also a researcher and clinical trialist. He designed and served as national principle investigator for several landmark studies, including Aspire 2, Levant 2, Superb, ACT 1, and NIH BEST-CLI trial. He is a leader in the cardiovascular world, having been elected to the Board of Governors of American College of Cardiology, immediate past-President of the MA ACC Chapter, and immediate past-President of the Society for Cardiovascular Angiography and Interventions (SCAI). Dr. Rosenfield is a founding member of VIVA, a 501c3 organization, and sits on its board of directors. At Massachusetts General Hospital, he is the Medical director of the PERT Program, which he founded with his colleagues; he also founded the National PERT Consortium, a 501c3 organization dedicated to improving management, outcomes, and awareness of Pulmonary Embolism, and he served as its initial President; he remains a member of the PERT Consortium Executive Committee.

Brian Schiro, MD, RPVI, FSIR is a Vascular and Interventional Radiologist with Baptist Heart and Vascular Care at the Miami Cardiac & Vascular Institute in Miami, FL. Dr. Schiro completed his fellowship training with Miami Cardiac & Vascular Institute in 2010 following his diagnostic radiology residency training at the University of Pittsburgh Medical Center. He received his medical degree from the Louisiana State University Health Sciences Center in 2004. Dr. Schiro now serves as the Program Director for the Independent Interventional Radiology Residency with Miami Vascular and is also the medical director for the medical sonography program at Nova Southeastern University. He is the medical director of the System-Wide Quality Assurance Committee for the Noninvasive Vascular Lab at Baptist Hospital Health South Florida. He also serves on the IAC Vascular Testing Board of Directors as a representative of the Society of Interventional Radiology (SIR). He has authored numerous articles in peer reviewed journals and his research interests include noninvasive imaging and diagnosis as well as aortic and peripheral vascular interventions.

Aditya M. Sharma, MBBS, FSVM, RPVI, is Professor of Cardiovascular Medicine at Wake Forest University School of Medicine and Medical Director of Vascular Medicine at Atrium Health’s Sanger Heart & Vascular Institute in Charlotte, North Carolina. He also serves as Medical Director of the Venous Thromboembolism Center of Excellence and Co-Director of the Vascular Laboratories. Across Advocate Health, he chairs the Enterprise Pulmonary Embolism Clinical Effectiveness Executive Council and leads the multistate Vascular Laboratory Consortium in North Carolina and Georgia.

Dr. Sharma serves as President of the Society for Vascular Medicine and served as Associate Editor of Vascular Medicine Journal. He chaired the Society’s 2026 Vascular Scientific Sessions. Before joining Atrium Health, he was a tenured Associate Professor at the University of Virginia, where he led the Vascular Medicine Program, directed the Vascular Medicine Fellowship, and directed the multidisciplinary Pulmonary Embolism Response Team.

His clinical and academic interests include pulmonary embolism, deep vein thrombosis, peripheral artery disease, fibromuscular dysplasia, and vascular ultrasound. His work emphasizes multidisciplinary care, evidence-based treatment, and the development of coordinated vascular programs to improve patient outcomes.

Dr. Sharma has authored more than 100 manuscripts and multiple book chapters and has contributed to national and international scientific statements and consensus documents. An active clinical investigator and educator, he regularly serves as invited faculty at national and international cardiovascular and vascular meetings.

A member of the Miami Cardiac & Vascular Institute and Miami Cancer Institute physician team, Dr. Gandhi specializes in minimally invasive treatments for peripheral vascular disease, cancer, and other diseases.

Dr. Gandhi did his undergraduate studies at Northwestern University and Harvard University. He graduated summa cum laude. He received his degree in medicine from Northwestern University Medical School, where he also graduated with honors. Following medical school, he completed a surgical internship at Cornell University Medical Center and New York Presbyterian Hospital. He completed his residency training and fellowship at UCLA Medical Center.

Dr. Gandhi also dedicated an entire year to biomedical research at Memorial Sloan-Kettering Cancer Center and also served as a research fellow at the National Institutes of Health (NIH). Prior to joining Miami Cardiac & Vascular Institute, he was an international visiting scholar at Asan Medical Center/University of Ulsan Medical School in Seoul, South Korea. He has published numerous scientific papers, authored several textbook chapters and presented his research at national and international meetings.

He is also a fellow of the Society for Vascular Medicine and a fellow of the Society of Interventional Radiology. He is the co-author of the textbook Interventional Oncology. Dr. Gandhi is also a program director for the International Symposium on Endovascular Therapy (ISET) and Symposium on Clinical Interventional Oncology (CIO).